SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-24-037160
Filing Date
2024-03-27
Accepted
2024-03-27 16:05:36
Documents
82
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K ikt-20231231.htm   iXBRL 10-K 2747380
2 EX-14.1 ikt-ex14_1.htm EX-14.1 92053
3 EX-21.1 ikt-ex21_1.htm EX-21.1 6485
4 EX-23.1 ikt-ex23_1.htm EX-23.1 10012
5 EX-31.1 ikt-ex31_1.htm EX-31.1 14740
6 EX-31.2 ikt-ex31_2.htm EX-31.2 14793
7 EX-32.1 ikt-ex32_1.htm EX-32.1 8949
8 EX-32.2 ikt-ex32_2.htm EX-32.2 8951
9 EX-97.1 ikt-ex97_1.htm EX-97.1 40497
10 GRAPHIC img35665305_0.jpg GRAPHIC 29111
11 GRAPHIC img35665305_1.jpg GRAPHIC 19718
  Complete submission text file 0000950170-24-037160.txt   8969063

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ikt-20231231.xsd EX-101.SCH 1265668
85 EXTRACTED XBRL INSTANCE DOCUMENT ikt-20231231_htm.xml XML 1113157
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

IRS No.: 263407249 | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-39676 | Film No.: 24790593
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)